Cardiometabolic digital diagnostics company Nanowear announced a licensing and data partnership with glucose monitoring specialist Dexcom to integrate glucose data from the Dexcom G7 into its SimpleSense nanotechnology-enabled wearable.
Nanowear offers home-based, AI-enabled digital diagnostics for cardiometabolic health. The company’s FDA-cleared SimpleSense wearable reads patient vitals, such as respiration rate, heart rate, blood pressure, physical activity, lung volume and more.
It uses cloth-based nanosensor technology to capture more than 120 million data points daily. The platform then uses AI to analyze the data and then generate reports for physicians on the data gathered.
Dexcom G7 is an FDA-cleared continuous glucose monitoring system worn on the back of the upper arm or upper buttocks that can be used by people with all types of diabetes and who are 2 years old and older. The wearable monitor measures blood sugar levels and sends glucose readings to a smartphone or app every five minutes.
Through the partnership, Nanowear will ingest glucose data from Dexcom G7’s continuous glucose monitoring system alongside Nanowear’s cardiovascular biomarkers, which the company says will allow clinical researchers to obtain real-world and real-time cardiometabolic diagnostic assessments.
“The promise of digital health over a decade ago was precision medicine and individualized care that would save patients, providers and payers time and money while promoting better outcomes and experience,” Venk Varadan, CEO and cofounder of Nanowear, told MobiHealthNews in an email.
“Gen 1 and Gen 2 solutions, while successful in building awareness, never truly accomplished this goal holistically and diagnostically. Being able to passively quantify the relationship via AI between glucose tolerance/insulin sensitivity and hypertension, arrhythmia, sleep apnea, heart failure, etc., is going to be a proven cardiometabolic solution in precision medicine and individualized care — and Nanowear can now do that.”
THE LARGER TREND
Nanowear received FDA clearance for its AI-enabled SimpleSense-BP and SimpleSense-BP Software Application in December 2023.
In 2021, the company received software-only FDA 510(k) clearance, enabling it to implement standalone AI and deep learning algorithms to inform remote diagnoses as software-as-a-medical device in forthcoming AI-based diagnostics in a closed-loop hospital-at-home network.
In November, Dexcom announced it made a $75 million strategic investment in health-tracking ring maker Oura, bringing its valuation to more than $5 billion. The companies also announced a strategic partnership to enable two-way data flow between Dexcom’s CGM and the Oura Ring.
Dexcom also announced it expanded its diabetes-management capabilities by offering direct connectivity to the Apple Watch for its G7 continuous glucose monitoring system via a dedicated Bluetooth connection.
The glucose monitoring company secured FDA clearance for its over-the-counter CGM tool, Stelo. The device is available without requiring a prescription, and the wearable biosensor boasts a battery life of up to two weeks and adheres to the back of the upper arm.
In 2023, Dexcom announced a partnership with digital chronic condition management platform DarioHealth to allow Dario’s digital health tools for metabolic health to include data from Dexcom CGMs.
Credit: Source link
